{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:49:14Z","timestamp":1761562154453},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.japh.2016.06.013","type":"journal-article","created":{"date-parts":[[2016,9,23]],"date-time":"2016-09-23T12:34:01Z","timestamp":1474634041000},"page":"670-676","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacist engagement within a hepatitis C ambulatory care clinic in the era of a treatment revolution"],"prefix":"10.1016","volume":"56","author":[{"given":"Timothy P.","family":"Gauthier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandria","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maribel","family":"Toro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara Z.","family":"Carrasquillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Corentin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.japh.2016.06.013_bib1","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1478-3231.2011.02494.x","article-title":"Hepatitis C virus infection in USA: an estimate of true prevalence","volume":"31","author":"Chak","year":"2015","journal-title":"Liver Int"},{"issue":"S1","key":"10.1016\/j.japh.2016.06.013_bib2","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1002\/hep.21064","article-title":"Therapy of hepatitis C: from empiricism to eradication","volume":"43","author":"Pawlotsky","year":"2006","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.japh.2016.06.013_bib3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/jama.2014.8897","article-title":"New expensive treatments for hepatitis C infection","volume":"312","author":"Brennan","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.japh.2016.06.013_bib4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/cid\/civ220","article-title":"The cost-effectiveness, heath benefits and financial costs of new antiviral treatments for hepatitis C virus","volume":"61","author":"Rein","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.japh.2016.06.013_bib5","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/cid\/civ545","article-title":"Hepatitis C management and the infectious diseases pharmacist","volume":"61","author":"Wenzler","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.japh.2016.06.013_bib6","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/phar.1512","article-title":"Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection. Joint opinion of the GI\/Liver\/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy","volume":"34","author":"Mohammad","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"7","key":"10.1016\/j.japh.2016.06.013_bib7","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1331\/JAPhA.2007.06136","article-title":"Chronic hepatitis C virus infection: a review for pharmacists","volume":"47","author":"Rodis","year":"2007","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"4","key":"10.1016\/j.japh.2016.06.013_bib8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MCG.0000000000000124","article-title":"Impact of provider type on hepatitis C outcomes with boceprevir-based and telaprevir-based regimens","volume":"49","author":"Li","year":"2015","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"5","key":"10.1016\/j.japh.2016.06.013_bib9","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1111\/liv.12729","article-title":"Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV\/HCV-coinfected patients can modify the adherence","volume":"35","author":"Gonzalez-Colominas","year":"2015","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.japh.2016.06.013_bib10","first-page":"433","article-title":"A\u00a0population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system","volume":"20","author":"Belperio","year":"2014","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"5","key":"10.1016\/j.japh.2016.06.013_bib11","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jhep.2013.06.019","article-title":"A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C","volume":"59","author":"Carrion","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.japh.2016.06.013_bib12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.18553\/jmcp.2009.15.2.147","article-title":"Pharmacist intervention in treatment of patients with genotype 1 chronic hepatitis C","volume":"15","author":"Marino","year":"2009","journal-title":"J\u00a0Manag Care Pharm"},{"issue":"2","key":"10.1016\/j.japh.2016.06.013_bib13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/1357633X13519043","article-title":"A\u00a0pharmacist-managed telemedicine clinic for hepatitis C care: a descriptive analysis","volume":"20","author":"You","year":"2014","journal-title":"J\u00a0Telemed Telecare"},{"key":"10.1016\/j.japh.2016.06.013_bib14","series-title":"Department of Veterans Affairs VHA Directive 1300.01. National Viral\u00a0Hepatitis Program","year":"2013"},{"issue":"6","key":"10.1016\/j.japh.2016.06.013_bib15","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1053\/j.gastro.2015.07.056","article-title":"Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013","volume":"149","author":"Beste","year":"2015","journal-title":"Gastroenterology"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319116307166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319116307166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T05:55:14Z","timestamp":1536386114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319116307166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1544319116307166"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2016.06.013","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}